Abstract: A process and system for controlled delivery of a biologically active substance to an animal body fluid which comprises contacting fluid with a reversible complex of a conjugate (1) and a binding macromolecule (2), wherein the conjugate (1) comprises a biologically active portion which is intended to be proportionately released into a body fluid stream in response to varying concentration levels of a component of the body fluid stream, and a complexing substrate portion which conjugates with the biologically active portion and which is characterized by affinity to the binding macromolecule (2), competitively or non-competitively with the variable component of the body fluid; thereby causing the component present in the body fluid to complex to the binding macromolecule and thus releasing the conjugate (1) therefrom into the fluid.The process and system are particularly applicable for the glucose-controlled release of insulin and other hypoglycemic agents in the treatment of diabetes.

Abstract: A high resolution position sensitive radiation detector for analyzing radiation emanating from a source, constructed of a thin plate having an elongated slot with conductive edges acting as a cathode, a charged anode wire positioned within 0.5 mm adjacent the source and running parallel to the slot and centered therein, an ionizable gas ionized by radiation emanating from the source provided surrounding the anode wire in the slot, a helical wire induction coil serving as a delay line and positioned beneath the anode wire for detecting gas ionization and for producing resulting ionization signals, and processing circuits coupled to the induction coil for receiving ionization signals induced therein after determining therefrom the location along the anode wire of any radiation emanating from the source. An ionization gas of 70% Ar, 29% Isobutane, 0.6% Freon 13BI, and 0.4% Methylal is used.

Abstract: The preparation of N.sup..alpha. -desacetylthymosin.alpha..sub.1 and its use as a hormonally active agent participating in the regulation, differentiation and function of thymic dependent lymphocytes (T-cells) is described.

Abstract: Sheep antiserum developed against the human glycohemoglobin, Hb A.sub.1c, distinguishes this fraction from the major component Hb A.sub.o. Partial cross relativity is observed with Hb A.sub.1a and Hb A.sub.1b, as well as with analogous glycohemoglobins from mouse and dog hemolysates. The reactivity of the hemoglobins with this specific antiserum is abolished by the reduction of the keto group of the sugar ligand. The immunological specificity displayed provides the basis of a quantitative assay for Hb A.sub.1c, which is suitable for studies of clinical and experimental diabetes.

Abstract: A plasminogen proactivator and a corresponding activator has been isolated from mammalian and avian, especially human, plasma which is characterized within a given species as a single, electrophoretically and immunologically homogeneous protein. The activator acts as a catalyst to initiate fibrinolytic activity in plasma and is therefore useful in controlling clotting which occurs, e.g. in venous thrombosis or arterial occulsion, and in diagnosing conditions which predispose to thromboembolic phenomena. The proactivator has a long useful in vivo half life and can be used to provide a reservoir for maintaining the fibrolytic potential of blood.

Abstract: A composition comprising from 0.02 to 17 parts by weight of glycerol per part by weight of an iron chelating agent selected from the group consisting of salicyl hydroxyamic acid; 2,3- and 3,4-dihydroxy benzoic acid; and halobenzohydroxamic; e.g., m-iodobenzohydroxamic acid and m-chlorobenzohydroxamic acid; as well as their C.sub.1 to C.sub.4 alkyl esters. When this composition is administered parenterally, it is found to block aerobic and anaerobic glucose catabolism and thereby accomplish control of several trypanosomes, including Trypanosoma brucei, T. gambiensi, T. rhodesiensi, T. equiperdum, T. evansi, T. congolense and T. vivax. In mammals, the therapeutic dosage is calculated to provide at least 138 mg/kg of body weight of glycerol and at least 96 mg/kg of body weight of the iron chelating agent.

Abstract: A posture training device includes in a mechanical-electrical embodiment thereof, an electrically conductive plate divided into two contact zones and slidable upon a support base of one housing section of the device. One end of the plate is operatively connected to a body harness cable extending around the longitudinal axis of the body from the pubis to the scapula, while the other end of the plate is electrically connected to spring-biased cable winding mechanisms.